The data were provided at the American Academy of Neurology annual meeting.

Additional Alemtuzumab Mechanism of Action Data Reported Genzyme Company reported four-year follow-up data from its completed Stage 2 multiple sclerosis trial showing an estimated 71 % of alemtuzumab treated sufferers remain free of clinically-active disease just as much as 3 years after most sufferers received their last span of the investigational compound. The data were provided at the American Academy of Neurology annual meeting sildenafil citrate . In the trial, alemtuzumab was presented with to patients in several annual cycles of not more than five days per routine, while Rebif was presented with to patients three times per week, every week for three years.